In recent years, weight-loss meds like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have gained significant attention in the United States. These drugs belong to a class known as GLP-1 medications, primarily developed for diabetes management but increasingly used for weight loss. As demand for these treatments rises, understanding the landscape of insurance coverage for these drugs becomes crucial for consumers. Weight-Loss Meds Insurance Coverage Overview Insurance coverage for GLP-1 weight-loss drugs is complex and varies significantly across different plans. While government-funded programs like Medicaid and those covering federal, state,…
Read MoreGovernment vs. Private: Who’s Really Paying for Your Weight-Loss Meds?
